Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerodalcibep vs. Evolocumab and Alirocumab in CVD Patients (LIBerate-H2H)
NCT04790513Phase 3Completed
- Sponsor
- LIB Therapeutics
- Start
- Apr 2021
- Primary completion
- Sep 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lerodalcibep in hypercholesterolemia and cardiovascular diseases (CVD) (3 arms), sponsored by LIB Therapeutics. Primary endpoint: LDL-C reduction from baseline at 12 weeks. Started Apr 2021; status: completed.
02
Drugs
lerodalcibep
03
Conditions
hypercholesterolemiacardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT04790513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04790513.